Neuroblastoma targeting by c-myb-selective antisense oligonucleotides entrapped in anti-GD2 immunoliposome: Immune cell-mediated anti-tumor activities

Chiara Brignole, Danilo Marimpietri, Gabriella Pagnan, Daniela Di Paolo, Marta Zancolli, Vito Pistoia, Mirco Ponzoni, Fabio Pastorino

Research output: Contribution to journalArticlepeer-review

Abstract

Liposome encapsulation of anticancer agents results in reduced side effects of the entrapped drug and improved therapeutic efficacy. The external surface of the lipidic envelope can be coupled with antibodies directed against tumor-associated antigens. The resulting immunoliposomes allow to increase the therapeutic index of cytotoxic drugs while minimizing their systemic toxicity. In this regard, the disialoganglioside GD2 is a very promising tumor-associated antigen since it is expressed at high intensity on human neuroblastoma cells, but is detected only in normal cerebellum and peripheral nerves. Immunoliposomes can be used as vectors to deliver antisense oligonucleotides to cancer cells with the aim to modulate oncogene expression. Furthermore, antisense oligonucleotides have attracted much interest because of their ability to stimulate immune responses. Here, we will describe a novel experimental therapeutic approach for neuroblastoma based on anti-GD2 liposomal c-myb-selective antisense oligonucleotides.

Original languageEnglish
Pages (from-to)181-186
Number of pages6
JournalCancer Letters
Volume228
Issue number1-2
DOIs
Publication statusPublished - Oct 18 2005

Keywords

  • Antisense oligonucleotides
  • C-myb
  • CpG motifs
  • GD
  • Immune responses
  • Targeted-liposomes

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology
  • Oncology

Fingerprint Dive into the research topics of 'Neuroblastoma targeting by c-myb-selective antisense oligonucleotides entrapped in anti-GD2 immunoliposome: Immune cell-mediated anti-tumor activities'. Together they form a unique fingerprint.

Cite this